Rhumbline Advisers lowered its stake in shares of Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN) by 8.7% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 25,513 shares of the company’s stock after selling 2,420 shares during the quarter. Rhumbline Advisers owned about 0.07% of Biohaven Pharmaceutical worth $1,008,000 at the end of the most recent reporting period.

A number of other hedge funds also recently made changes to their positions in BHVN. BlackRock Inc. increased its position in Biohaven Pharmaceutical by 63.6% during the first quarter. BlackRock Inc. now owns 1,888,608 shares of the company’s stock worth $48,650,000 after acquiring an additional 734,401 shares during the period. Foresite Capital Management IV LLC increased its holdings in Biohaven Pharmaceutical by 298.8% in the 1st quarter. Foresite Capital Management IV LLC now owns 851,200 shares of the company’s stock valued at $21,927,000 after buying an additional 637,765 shares during the period. Northern Trust Corp increased its holdings in Biohaven Pharmaceutical by 158.5% in the 1st quarter. Northern Trust Corp now owns 303,830 shares of the company’s stock valued at $7,827,000 after buying an additional 186,274 shares during the period. Sphera Funds Management LTD. bought a new stake in Biohaven Pharmaceutical in the 1st quarter valued at $3,377,000. Finally, Eventide Asset Management LLC increased its holdings in Biohaven Pharmaceutical by 43.0% in the 1st quarter. Eventide Asset Management LLC now owns 346,000 shares of the company’s stock valued at $8,913,000 after buying an additional 104,000 shares during the period. 80.85% of the stock is currently owned by institutional investors and hedge funds.

Shares of Biohaven Pharmaceutical stock opened at $35.86 on Tuesday. Biohaven Pharmaceutical Holding Co Ltd has a 52-week low of $16.50 and a 52-week high of $44.28.

Several equities research analysts have issued reports on BHVN shares. Canaccord Genuity reissued a “buy” rating and issued a $35.00 price target on shares of Biohaven Pharmaceutical in a report on Tuesday, May 22nd. ValuEngine raised shares of Biohaven Pharmaceutical from a “hold” rating to a “buy” rating in a report on Friday, June 1st. Piper Jaffray Companies set a $48.00 price target on shares of Biohaven Pharmaceutical and gave the company a “buy” rating in a report on Friday, June 8th. Cantor Fitzgerald started coverage on shares of Biohaven Pharmaceutical in a report on Monday, June 11th. They issued a “buy” rating and a $42.00 price target on the stock. Finally, Zacks Investment Research raised shares of Biohaven Pharmaceutical from a “strong sell” rating to a “hold” rating in a report on Wednesday, June 13th. Two investment analysts have rated the stock with a sell rating, two have assigned a hold rating and six have issued a buy rating to the stock. The company has an average rating of “Hold” and an average price target of $47.29.

About Biohaven Pharmaceutical

Biohaven Pharmaceutical Holding Company Ltd., a clinical-stage biopharmaceutical company, develops product candidates to treat neurological diseases, including rare disorders. Its lead product candidate is rimegepant, which is in Phase III clinical trials for the acute treatment of migraine. The company also develops trigriluzole, which is in a Phase II/III clinical trial used for the treatment of ataxias with an initial focus on spinocerebellar ataxia; and Phase II/III clinical trial for the treatment of obsessive compulsive disorders, as well as for the treatment of Alzheimer's diseases.

Featured Article: Short Selling Stocks, A Beginner’s Guide

Institutional Ownership by Quarter for Biohaven Pharmaceutical (NYSE:BHVN)

Receive News & Ratings for Biohaven Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biohaven Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.